191 related articles for article (PubMed ID: 36332464)
1. Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.
Harahsheh E; Callister M; Hasan S; Gritsch D; Valencia-Sanchez C
J Neuroimmunol; 2022 Dec; 373():577994. PubMed ID: 36332464
[TBL] [Abstract][Full Text] [Related]
2. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
[TBL] [Abstract][Full Text] [Related]
3. Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration?
Motahharynia A; Naghavi S; Shaygannejad V; Adibi I
Mult Scler Relat Disord; 2022 Oct; 66():104035. PubMed ID: 35858498
[TBL] [Abstract][Full Text] [Related]
4. Severe disease exacerbation after mRNA COVID-19 vaccination unmasks suspected multiple sclerosis as neuromyelitis optica spectrum disorder: a case report.
Lohmann L; Glaser F; Möddel G; Lünemann JD; Wiendl H; Klotz L
BMC Neurol; 2022 May; 22(1):185. PubMed ID: 35585528
[TBL] [Abstract][Full Text] [Related]
5. First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2.
Umezawa S; Ioka K; Aizawa S; Tashiro Y; Yoshizawa K
Neurol Sci; 2023 Feb; 44(2):451-455. PubMed ID: 36289118
[TBL] [Abstract][Full Text] [Related]
6. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
Paybast S; Emami A; Baghalha F; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
[TBL] [Abstract][Full Text] [Related]
8. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
10. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.
Chen S; Fan XR; He S; Zhang JW; Li SJ
Neurol Sci; 2021 Sep; 42(9):3537-3539. PubMed ID: 34189662
[TBL] [Abstract][Full Text] [Related]
11. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
[TBL] [Abstract][Full Text] [Related]
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
13. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
[TBL] [Abstract][Full Text] [Related]
14. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
16. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience.
Martín-Nares E; Hernandez-Molina G; Fragoso-Loyo H
Lupus; 2019 Oct; 28(11):1302-1311. PubMed ID: 31566079
[TBL] [Abstract][Full Text] [Related]
18. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
[TBL] [Abstract][Full Text] [Related]
19. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
20. Targeting the complement system in neuromyelitis optica spectrum disorder.
Asavapanumas N; Tradtrantip L; Verkman AS
Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
